Deutsche Biotech Innovativ AG

Share Issue/Capital Change • Sep 25, 2015

News Details

Corporate | 25 September 2015 12:26

Deutsche Biotech Innovativ AG: Subscrition price for capital increase against cash contribution fixed at EUR 33.50

DGAP-News: Deutsche Biotech Innovativ AG / Key word(s): Capital Increase

2015-09-25 / 12:26

---

CORPORATE NEWS

Deutsche Biotech Innovativ AG:

Subscrition price for capital increase against cash contribution fixed at EUR 33.50

Hennigsdorf, 25 September 2015 – With consent of the Supervisory Board, the Management Board of Deutsche Biotech Innovativ AG (“DBI”) fixed the subscription price for the planned capital increase at EUR 33.50 per share. In the context of a capital increase against cash contribution, which had been resolved by the annual general meeting of DBI AG in July, up to 596,400 new shares shall be issued. By this, DBI aims at raising gross proceeds of around EUR 20 million.

The new shares shall be offered to the existing shareholders via preemptive rights for the named subscription price of EUR 33.50 per share and for a period of at least two weeks. Any shares not subscribed after the end of the subscription period will be offered to the shareholders and interested investors for subscription. The capital increase shall be conducted until November 2015 at the latest based on a securities prospectus, which is still to be published.

About Deutsche Biotech Innovativ AG

Deutsche Biotech Innovativ AG (“DBI”) is a biotechnology company that uses innovative blood biomarkers to research and clinically develop unique therapeutic solutions for serious illnesses for which no adequate medical solutions have yet been found. Its focus is on drugs for sepsis and cancer. The company’s main product is the patented drug Adrecizumab for decreasing mortality due to organ failure in septic shock. Adrecizumab has successfully completed the preclinical phase and will be tested in a Phase I study starting in 2015.

The preclinical and clinical studies are mainly carried out by project companies in which DBI AG holds a stake. Currently, DBI AG holds 26% of AdrenoMed AG (Agent: Adrecizumab), 25% of Oncoprevent GmbH (Agent: DB1RA), 100% of AngioBiomed GmbH (Agent: AB2302) and 50% of My Life Diagnostics GmbH (Diagnostic agent for urinary tract infection).

DBI aims to further expand its drug pipeline and invest in the research and development of drugs that have high unique-selling-point potential.

Both members of DBI’s Management Board, Dr. Bernd Wegener and Dr. Andreas Bergmann, have many years of experience in the biotechnology field. Both were founders and part of the management team of B.R.A.H.M.S. AG, a highly successful biotechnology company specialising in the identification of blood biomarkers for treating serious illnesses. It was sold in 2009 for around EUR 330 million. Dr. Bernd Wegener is also a member of the Executive Board of the Association of the German Pharmaceutical Industry (Bundesverband der Pharmazeutischen Industrie).

For more information, please contact:

Deutsche Biotech Innovativ AG

Ms. Susanne Wallace

Tel.: +49 (0)3302 20 77 811

E-Mail: s.wallace@dbi-ag.de

Kirchhoff Consult AG

Ms. Anja Ben Lekahl

Tel.: +49 (0)40 609 186 55

E-Mail: anja.benlekhal@kirchhoff.de

DISCLAIMER

This announcement does not constitute an offer to buy shares or other securities of Deutsche Biotech Innovativ AG and does not replace the prospectus. Investment decisions with respect to the shares or other securities of Deutsche Biotech Innovativ AG shall only take place on the basis of the prospectus which will be available after the approval by the German Financial Supervisory Authority (BaFin) free of charge at Deutsche Biotech Innovativ AG.

This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the “United States”), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”) and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan.

The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

---

2015-09-25 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG.

The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Media archive at www.dgap-medientreff.de and www.dgap.de

---

397591  2015-09-25